Clinical Study On The Treatment Of Spleen And Stomach Dampness-heat Syndrome Of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With Huashi-Zhixie Formula

Objective: To observe the clinical effect of Huashi-Zhixie prescription on spleen and stomach dampness-heat syndrome of diarrhea-predominant irritable bowel syndrome(IBS-D),to provide certain clinical data support for the clinical application of Huashi-Zhixie prescription,and to broaden the clinical diagnosis and treatment ideas and methods of spleen and stomach dampness-heat syndrome of IBS-D.Methods: A total of 60 IBS-D patients with spleen-stomach damp-heat syndrome who were treated in the Department of Spleen-Stomach Diseases of Zibo Hospital of Traditional Chinese Medicine from December 2021 to December 2022 were selected as the research objects.They were randomly divided into the treatment group and the control group,with 30 cases in each group.The treatment group was given Huashi Zhixie prescription(ginger pinellia rhizoma9 g,Poria cocos 15 g,Tangerine peel 12 g,Peran 12 g,fried Atractylode rhizoma30 g,Coix seed 15 g,Zhebei 15 g,cutotheca mantidis 30 g,peppermint 6g,white peony 15 g,Fengfeng 9g,Evodia officinalis 6g,dried ginger 6g,licorice 6g)in the morning and evening after meal.The control group was treated with trimebutine maleate dispersible tablets 0.1g/time,3 times/day,orally after meals.Both groups were treated for 4 weeks.The basic information of the two groups was recorded,the efficacy evaluation indexes before and after treatment were observed in the two groups,and the recurrence rate was recorded after 4 weeks of drug withdrawal.And then,after statistical analysis,the therapeutic effects of the two groups were compared.Results:1.IBS-SSS : after treatment,the IBS-SSS scores in the two groups were lower than before(P<0.05),and the IBS-SSS score in the treatment group was lower than that in the control group(P<0.05).Both groups have a certain effect on improving the symptoms of irritable bowel syndrome,and the treatment group is better than the control group.2.IBS-QOL : after treatment,the IBS-QOL scores in the two groups were lower than before(P<0.05),and there was no significant difference between the treatment group and the observation group after treatment(P>0.05).The two groups have similar effects on improving the quality of life of patients.3.TCM Symptom assessment Scale: After treatment,the main symptoms and secondary symptoms of TCM in the treatment group were improved,and the difference was statistically significant(P<0.05).The secondary symptoms of dry mouth and no desire to drink,bitter mouth and halitosis,anal burning in the control group were not significantly improved(P>0.05).The other main symptoms and secondary symptoms were improved(P<0.05).After treatment,the effect of the treatment group was better than that of the control group in the five symptoms of the frequency of pain and diarrhea,difficult defecation or urgency of defecation,smelly stool,dry mouth and no desire to drink or bitter mouth and bad breath,and anal burning(P<0.05).There was no significant difference in the improvement of abdominal pain,stool character and emotional abnormality between the two groups(P>0.05).4.TCM syndrome curative effect: the total effective rate of the treatment group was 90.00%,the control group was 76.67%,the total effective rate of the treatment group was higher than that of the control group,the treatment effect of IBS-D was better than that of the control group,the difference was statistically significant(P<0.05).5.Long-term efficacy: 4 weeks after drug withdrawal,the recurrence rate was 18.52% in the treatment group and 47.83% in the control group.The recurrence rate of the treatment group was lower than that of the control group,and the long-term effect was better than that of the control group,the difference was statistically significant(P<0.05).6.Safety: there were no obvious adverse reactions in the two groups during the study,and there were no significant changes in the laboratory examination indexes before and after treatment.The drug safety evaluation criteria of the two groups were grade Ⅰ.Conclusion: Huashizhixie Decoction is superior to trimebutine maleate in the treatment of IBS-D with spleen-stomach damp-heat syndrome,which can better improve the clinical symptoms of patients,and has better long-term efficacy.No adverse reactions occur in the treatment process,and the therapeutic effect is safe and reliable.